HIGHLIGHTS
- who: Tulsi Shah and collaborators from the (UNIVERSITY) have published the paper: Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review, in the Journal: (JOURNAL)
- what: Five patients in this study reported an adverse effect considered mild to moderate in severity. This analysis showed that the average steady_state decrease in the concentration of free CGRP of galcanezumab at 120 mg monthly was 61% and 240 mg was 76%, though of note, these concentrations did vary from initial time of administration to the end of the month.
- how: The results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.